ArticleCancer medicine2026
A Population-Based Nomogram for Predicting Overall Survival in Pulmonary Sarcomatoid Carcinoma With Real-World External Validation.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPulmonary sarcomatoid carcinoma (PSC) is a rare and highly aggressive tumor. This study aimed to investigate the prognostic factors of PSC and develop a new risk classifier to predict patients' overall survival (OS).
methodsThis retrospective study consisted of 675 PSC patients registered in the Surveillance, Epidemiology, and End Results (SEER) database, and 90 patients from the First Affiliated Hospital of Xi'an Jiaotong University. The univariate and multivariate Cox regression analyses were adopted to select the best prognostic variables. A nomogram was developed to predict the OS of these patients. The nomogram was assessed using receiver operating characteristic (ROC) curves, the concordance index (C-index), and calibration curves. Decision curve analysis (DCA) was adopted to assess its net clinical benefit. Additionally, a Lasso-Cox regression model was utilized to explore prognostic factors in real-world patients with PSC.
resultsThe multivariate analysis revealed that sex, T, N, and M stages, surgery, radiation, chemotherapy, and liver metastasis were independent prognostic factors of OS for patients with PSC, and a nomogram was developed to predict the OS of these patients. The ROC curves and the estimated C-index displayed that the nomogram yielded excellent performance in predicting OS. Calibration curves demonstrated satisfactory consistency between the actual and predicted OS. DCA illustrated that the nomogram would provide significant net clinical benefits. Consistent findings were discovered in the internal and external validation cohorts. Lasso-Cox regression models revealed that surgery and immunotherapy were key protective factors for OS, while ECOG ≥ 2, underlying medical history, and distant metastasis constituted major risk factors for OS.
conclusionsThe constructed nomogram is a reliable risk classifier to achieve personalized survival probability prediction for patients with PSC. Real-world data suggest that immunotherapy is associated with significantly prolonged survival in patients with PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.